36 results about "Peg plga" patented technology

The invention discloses an LID-PEG-PLGA controlled-release nano microsphere and a preparation method thereof. The microsphere is the controlled-release microsphere which contains medicinal lidocaine and a degradable carrier. The degradable carrier contains polylactic-glycolic acid and PEG-2000. The mass percentage of the lidocaine in the controlled-release microsphere is 30 to 35 percent. The preparation method comprises the following steps of: preparing the carrier into matrix solution; dispersing the lidocaine into the matrix solution and preparing the lidocaine into an oil phase; mixing the oil phase and the aqueous solution of polyvinyl alcohol, and performing ultrasonic emulsification on the mixture under a water bath condition to obtain W / O-type protogala; mixing the W / O-type protogala and the aqueous solution of polyvinyl alcohol again, and further emulsifying the mixture into W / O / W-type complex emulsion; volatilizing the emulsion by reducing pressure at the normal temperature to obtain cured lidocaine-carried nano microsphere; and scattering, blending, packaging, freezing, sterilizing and the like. The medicament loading rate of the controlled-release nano microsphere can be up to 15 to 22 percent; the entrapment rate can be up to 68 to 78 percent; and the half-life period can be prolonged to 3 to 4 days. Therefore, the microsphere has relatively good effect of burst in the first day after the microsphere is taken and good effect of slow release in later days.

The invention discloses a caprolactone-lactic acid-glycollic acid segmented copolymer modified by polyethylene glycol 1000 vitamin E succinic acid ester, a preparation method and applications thereof. The segmented copolymer is prepared by forming an ester bond by combing hydroxyl in polyethylene glycol 1000 vitamin E succinic acid ester and carboxyl in a construction unit A; and the construction unit A is a polymer by connecting polycaprolactone, polylactic acid and polyglycolic acid through the ester bond. The copolymer has excellent biodegradability, biocompatibility and nontoxicity, improves and regulates hydrophilcity and biodegradation rate of aliphatic polyester. The segmented copolymer is a new biodegradable polymer, and has wide biomedical applications.

The invention discloses a PEG-PLGA sustained release microsphere with encapsulated buprenorphine and a preparation method thereof. The preparation method is as below: conducting debydrochlorination on buprenorphine to prepare alkali, and conducting a single emulsion method to obtain the PEG-PLGA sustained release microsphere with encapsulated buprenorphine. The weight ratio of buprenorphine (calculated by buprenorphine hydrochloride) to polyethylene glycol-polylactic acid-glycolic acid copolymer is 2-6:10, and the buprenorphine sustained release microsphere has particle size of 10-50 micron. The invention employs for the first time the hydrochloric acid-single emulsion method to prepare the buprenorphine sustained release microspheres with high drug loading, obvious sustained-release effect and good biocompatibility, and can develop a variety of administration approaches, such as intravenous injection, and subcutaneous and intramuscular non-intravenous administration approaches. The invention has good application prospect, and can improve patient compliance.

The invention discloses hemoglobin oxygen carrier-PEG-PLGA encapsulated hemoglobin. The PEG-PLGA encapsulated hemoglobin is obtained by encapsulating the hemoglobin with polyethylene glycol-poly(lactide-co-glycolide) (PEG-PLGA) nanoparticles. The hemoglobin is uniform in particle size distribution, good in dispersibility and high in oxygen appetency and has good oxygen supply effect and can be used for the system with general or partial anoxia or the system needing in vitro oxygen supply. The hemoglobin oxygen carrier-PEG-PLGA encapsulated hemoglobin plays an important role in the medical field when serving as a blood substitute and has a broad application prospect.

The invention belongs to the technical field of degradable materials, particularly relates to a biodegradable material and a preparation method, and provides the following scheme aiming at the problems that an existing degradable material is relatively high in cost and a preparation method is complicated. The degradable plastic material comprises the following important components: 40-50 parts of a plant straw component, 6-8 parts of modified starch, 3-6 parts of degradable plastic resin, 3-6 parts of polystyrene, 2-4 parts of polyglycolic acid, 1.2-2.4 parts of a flexibilizer, 3-6 parts of a hydrophobic auxiliary agent, 2-5 parts of a liquid thickener, 0.3-0.6 part of an antioxidant and 0.3-0.6 part of a preservative, and the straw component comprises corn straw powder, wheat straw powder, rice straw powder and soybean straw powder. The mass ratio of the corn straw powder to the wheat straw powder to the rice straw powder to the soybean straw powder is 1: 1: 1: 1. The material is prepared from waste plant straw components so that the cost can be reduced, and the material has an environment-friendly function; the preparation method is simple.

The invention discloses a hydrophilic membrane. The hydrophilic membrane is characterized by comprising a hydrophilic fiber membrane and a hydrophilic coating, wherein the hydrophilic fiber membrane is coated with the hydrophilic coating; the hydrophilic fiber membrane is prepared from the following raw materials in parts by mass: 40 to 60 parts of modified starch resin, 20 to 30 parts of polyglycolic acid and 1 to 4 parts of cyanoguanidine; the modified starch resin comprises the following raw materials in parts by mass: 30-50 parts of glutinous rice starch, 20-30 parts of acrylic resin, 0.5-1 part of an initiator, 30 parts of a solvent and 20 parts of a NaOH solution; the hydrophilic coating comprises the following raw materials in parts by mass: 100 parts of an acrylic copolymer, 30-50 parts of deionized water and 20-30 parts of polyvinyl alcohol. The invention also discloses a preparation method of the hydrophilic membrane. Compared with the prior art, the hydrophilic membrane disclosed by the invention is safe, healthy, good in water absorption and water retention effects and degradable.

The invention discloses resveratrol and temozolomide double-medicine-loaded nanospheres, which are prepared by mixing temozolomide (TEM), resveratrol (RES) and a medicine-loading material, wherein the medicine-loading material is an amphiphilic segmented copolymer, namely, polycaprolactone-polyethyleneglycol (mPEG-PCL) or polylactic acid-polyethyleneglycol (mPEG-PLA) or polyglycolic acid-polyethyleneglycol (mPEG-PLGA) synthesised by polycaprolactone or polylactic acid or polyglycolic acid and polyethyleneglycol. The preparation method comprises the following steps of: dissolving the two raw material constituents, namely, the resveratrol (RES) and the medicine-loading material, in a water-soluble non-toxic organic solvent, and dissolving temozolomide in pure water, and stirring; filtering the obtained light-blue dispersion liquid by a microfiltration membrane having a mesh diameter of 220+30 nm to obtain anti-tumour double-medicine-loaded nanosphere solution having a particle diameter of 80-120 nm; and heat-drying or freeze-drying.

The invention discloses a hemoglobin oxygen carrier, PEG-PLGA, to encapsulate hemoglobin. The PEG-PLGA encapsulated hemoglobin of the present invention is the encapsulated hemoglobin obtained by encapsulating the hemoglobin with polyethylene glycol-polylactic acid glycolic acid block copolymer (PEG-PLGA) nanoparticles, the particle size distribution is uniform, the dispersibility is good, and the oxygen It has high affinity and good oxygen supply effect, and can be used in systemic or local hypoxia, or in systems that require oxygen supply in vitro. The hemoglobin oxygen carrier-PEG-PLGA encapsulated hemoglobin of the present invention will play an important role in the medical field as a blood substitute, and has broad application prospects.

The invention discloses a polyglycolic-acid-orientation nanometer fiber bundle and a preparing method thereof. The fiber bundle is formed by polyglycolic acid nanometer fibers wrapped with a polylactic acid-hydroxyacetic acid copolymer. According to the preparing method, the molecular weight, the optical isomer content and the mixing ratio of polylactic acid and polyglycolic acid are preferred, and polylactic acid / polyglycolic acid blend fibers are produced at the suitable spinning temperature and the spinning speed. Under the specific conditions such as the preferred raw material components and sufficiently-strong stretch flow fields, the polyglycolic acid nanometer fibers (the average diameter is 50 nanometers to 200 nanometers) are in-situ formed in the forming process of the polylacticacid / polyglycolic acid blend fibers. The directional-arrangement polyglycolic-acid-orientation nanometer fiber bundle has excellent heat resistance, can keep the stability of the size and the orientation structure at the temperature of being higher than 120 DEG C, and has good degradability resistance, and a performance bottleneck that a conventional polyglycolic-acid nanometer fiber bundle is easy to disorientate and easy to degrade is broken through.

The invention discloses a Pep-1 peptide modified gliomas targeted nano drug delivery system and a preparation method thereof. The nano drug delivery system comprises polymer nano particles prepared by using an amphiphilic block copolymer (Pep-PEG-PLGA) as a carrier material, paclitaxel wrapped and carried by the polymer nano particles, and modified ligand Pep-1 polypeptide on the surfaces of the polymer nano particles. The amphiphilic block copolymer (Pep-PEG-PLGA) is composed of Male-PEG-PLGA and MePEG-PLGA, Pep-1 is adopted as a molecule with targeting function, the amphiphilic block copolymer PEG-PLGA is taken as a carrier material, the Pep-1 polypeptide is modified on the carrier material via covalent binding, and gliomas targeted polymer nano particles are prepared. According to the Pep-1 peptide modified gliomas targeted nano drug delivery system, gliomas targeting can be voluntarily performed, and the uptaking and accumulation of an anti-tumour drug in the gliomas part can be improved, as a result, the gliomas therapeutic effect is improved.

The invention discloses a chitin reinforced PGA-PLA composite material with a controllable degradation period as well as a preparation method and application thereof. The composite material comprises the following components in parts by weight: 10-50 parts of polyglycolic acid (PGA), 50-90 parts of polylactic acid (PLA), 2-15 parts of a toughening agent, 0-1 part of a hydrolysis-resistant agent and 10-40 parts of carapace powder. The composite material disclosed by the invention not only has excellent processability and mechanical property, but also has a controllable degradation period, so that the composite material can be used in fields with corresponding requirements on the degradation period.

The invention discloses an LID-PEG-PLGA controlled-release nano microsphere and a preparation method thereof. The microsphere is the controlled-release microsphere which contains medicinal lidocaine and a degradable carrier. The degradable carrier contains polylactic-glycolic acid and PEG-2000. The mass percentage of the lidocaine in the controlled-release microsphere is 30 to 35 percent. The preparation method comprises the following steps of: preparing the carrier into matrix solution; dispersing the lidocaine into the matrix solution and preparing the lidocaine into an oil phase; mixing the oil phase and the aqueous solution of polyvinyl alcohol, and performing ultrasonic emulsification on the mixture under a water bath condition to obtain W / O-type protogala; mixing the W / O-type protogala and the aqueous solution of polyvinyl alcohol again, and further emulsifying the mixture into W / O / W-type complex emulsion; volatilizing the emulsion by reducing pressure at the normal temperature to obtain cured lidocaine-carried nano microsphere; and scattering, blending, packaging, freezing, sterilizing and the like. The medicament loading rate of the controlled-release nano microsphere can be up to 15 to 22 percent; the entrapment rate can be up to 68 to 78 percent; and the half-life period can be prolonged to 3 to 4 days. Therefore, the microsphere has relatively good effect of burst in the first day after the microsphere is taken and good effect of slow release in later days.

A nanoformulation that includes nanoparticles. Each nanoparticle includes a shell in which a glycosaminoglycan (GAG is encapsulated. The GAG is ionically or covalently bonded to the shell. The GAG is selected from the group consisting of sulfated non-anticoagulant heparin (SNACH), super-sulfated non-anticoagulant heparin (S-SNACH), and a combination thereof. The shell includes Poly (lactic-co-glycolic acid) (PLGA), Polyethylene Glycol (PEG)-PLGA, maleimide-PEG-PLGA, chitosan, chitosan-PLGA, methoxy-polyethyleneglycol-poly (lactide-co-glycolide) (MPEG-PLGA)-(maleimide-PEG-PLGA), PLGA-Polycaprolate, or calcium alginate. A method of using the nanoformulation to treat a cancer in a subject includes administering to the patient a therapeutically effective amount of the nanoformulation for treating the cancer.